31May 2022
Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta‐analysis

Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta‐analysis

Head and neck squamous cell carcinoma (HNSCC) is among the common tumors associated with high mortality. Meta-analysis aimed to determine how additional anti‐epidermal growth factor receptor (EGFR) therapy to standard chemotherapy affects the progression‐free (PFS) and overall survival (OS) of the patients, besides the most common side effects. The addition of EGFR inhibitors to conventional chemotherapy significantly decreased the death and disease progression mortality. In the EGFR inhibitor group, the study revealed an increased chance of the over Grade 3 skin rashes and all Grade skin rashes. Despite their unwanted dermatological side effects, the addition of EGFR inhibitors is recommended to be included in advanced HNSCC therapy.

  • #dentistry

Like

Save

Share